stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) Total debt
Neogen Corporation's total debt at the end of fiscal 2026 was $793.7M, down 11.2% from $894.1M in fiscal 2025. At the end of the quarter to 31 August 2026 it was $774.2M. Over the past ten years it has ranged from $1.0M (fiscal 2022) to $894.1M (fiscal 2025); the current reading is higher than 57% of that period. Neogen Corporation ranks 23rd of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2026 | $793.7M | (11.23%) |
| FY2025 | $894.1M | 0.37% |
| FY2024 | $890.8M | 0.27% |
| FY2023 | $888.4M | 88,743.90% |
| FY2022 | $1.0M | 0.00% |
| FY2021 | $1.0M | 0.00% |
| FY2020 | $1.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Aug 2026 | $774.2M | (2.46%) |
| May 2026 | $793.7M | 0.05% |
| Feb 2026 | $793.3M | 0.05% |
| Nov 2025 | $792.9M | 0.05% |
| 19 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ITGR Integer Holdings Corporation compare | $1.3B |
| NEOG Neogen Corporation | $774.2M |
| ESTA Establishment Labs Holdings Inc. compare | $261.7M |
| UFPT UFP Technologies, Inc. compare | $96.0M |
| TMDX TransMedics Group, Inc. compare | $54.8M |
| INSP Inspire Medical Systems, Inc. compare | $25.2M |
| BFLY Butterfly Network, Inc. compare | $23.4M |
| AXGN AxoGen, Inc. compare | $17.6M |
| ALMR Alamar Biosciences, Inc. compare | $9.9M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on NEOG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement